Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT StudyFootnote^*

^*The SPIRIT study was conducted in accordance with the Declaration of Helsinki. The protocol was reviewed and approved by central of site-specific institutional review boards or ethics committees. All participants gave written informed consent.

References

• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed April 8, 2015.
   Google Scholar
• Huldrych F, Gunthard HF, Aberg JA, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA panel. JAMA. 2014;312:410–425.
   PubMed Web of Science ®Google Scholar
• Verhofstede C, Noë A, Demecheleer E, et al. Drug-resistant variants that evolve during nonsuppressive therapy persist in HIV-1-infected peripheral blood mononuclear cells after long-term highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2004;35:473–483.10.1097/00126334-200404150-00005
   PubMed Web of Science ®Google Scholar
• Palmisano L, Galluzzo CM, Giuliano M. The importance of testing genotypic resistance in proviral DNA of patients fully responding to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2009;51:233–234.10.1097/QAI.0b013e3181a5b247
   PubMed Web of Science ®Google Scholar
• Chew CB, Potter SJ, Wang B, et al. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART. J Clin Virol. 2005;33:206–216.10.1016/j.jcv.2004.11.006
   PubMed Web of Science ®Google Scholar
• Gilead Sciences Ltd. EVIPLERA 200 mg/25 mg/245 mg film coated tablets. Summary of Product Characteristics. Cambridge, UK. Revised December 2013; 2013.
   Google Scholar
• Gilead Sciences Inc. COMPLERA® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) tablets. US Prescribing Information. Foster City, CA. Revised June 2014; 2014.
   Google Scholar
• Palella FJ, Fisher M, Tebas P, et al. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants. AIDS. 2014;28:335–344.10.1097/QAD.0000000000000087
   PubMed Web of Science ®Google Scholar
• Armitage AE, Katzourakis A, de Oliveira T, et al. Conserved footprints of APOBEC3G on hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences. J Virol. 2008;82:8743–8761.10.1128/JVI.00584-08
   PubMed Web of Science ®Google Scholar
• Piantadosi A, Humes D, Chohan B, McClelland RS, Overbaugh J. Analysis of the percentage of human immunodeficiency virus type 1 sequences that are hypermutated and markers of disease progression in a longitudinal cohort, including one individual with a partially defective Vif. J Virol. 2009;83:7805–7814.10.1128/JVI.00280-09
   PubMed Web of Science ®Google Scholar
• Knoepfel SA, Di Giallonardo F, Däumer M, Thielen A, Metzner kJ. In-depth analysis of G-to-A hypermutation rate in HIV-1 env DNA induced by endogenous APOBEC3 proteins using massively parallel sequencing. J Virol Methods. 2011;171:329–338.10.1016/j.jviromet.2010.11.016
   PubMed Web of Science ®Google Scholar
• Kieffer TL, Kwon P, Nettles RE, Han Y, Ray SC, Siliciano RF. G->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol. 2005;79:1975–1980.10.1128/JVI.79.3.1975-1980.2005
   PubMed Web of Science ®Google Scholar
• Armitage AE, Deforche K, Chang CH, et al. APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete “all or nothing” phenomenon. PLoS Genet. 2012;8:e1002550.10.1371/journal.pgen.1002550
   PubMed Web of Science ®Google Scholar
• Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000;44:920–928.10.1128/AAC.44.4.920-928.2000
   PubMed Web of Science ®Google Scholar
• Porter DP, Kulkarni R, Fralich T, Miller MD, White KL. 96-week resistance analyses of the STaR study: Rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects. HIV Clin Trials. 2015;16:30–38.10.1179/1528433614Z.0000000009
   PubMed Web of Science ®Google Scholar
• Rimsky L, Van Eygen V, Hoogstoel A, et al. 96-week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials. Antivir Ther. 2013;18:967–977.
   PubMed Web of Science ®Google Scholar
• Rokx C, Verbon A, Rijnders B. Successful switch to rilpivirine/tenofovir/emtricitabine in HIV-1-infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy. HIV Med. 2014;15:611–614.
   PubMed Web of Science ®Google Scholar
• Amiel C, Schneider V, Guessant S, et al. Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in ‘real life’. J Antimicrob Chemother. 2014;69:3335–3339.10.1093/jac/dku294
   PubMed Web of Science ®Google Scholar
• Kabamba-Mukadi B, Duquenne A, Henrivaux P, et al. HIV-1 proviral resistance mutations: usefulness in clinical practice. HIV Med. 2010;11:483–492.
   PubMed Web of Science ®Google Scholar
• Ghosn J, Pellegrin I, Goujard C, et al. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS. 2006;20:159–170.10.1097/01.aids.0000199820.47703.a0
   PubMed Web of Science ®Google Scholar
• Wirden M, Soulie C, Valantin MA, et al. Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia. J Antimicrob Chemother. 2011;66:709–712.10.1093/jac/dkq544
   PubMed Web of Science ®Google Scholar
• Delaugerre C, Braun J, Charreau I, et al. Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication. HIV Med. 2012;13:517–525.
   PubMed Web of Science ®Google Scholar
• Saracino A, Gianotti N, Marangi M, et al. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART. J Med Virol. 2008;80:1695–1706.10.1002/jmv.v80:10
   PubMed Web of Science ®Google Scholar
• Vicenti I, Razzolini F, Saladini F, Romano L, Zazzi M. Use of peripheral blood DNA for genotype antiretroviral resistance testing in drug-naive HIV-infected subjects. Clin Infect Dis. 2007;44:1657–1661.10.1086/518287
   PubMed Web of Science ®Google Scholar
• Turriziani O, Bucci M, Stano A, et al. Genotypic resistance of archived and circulating viral strains in the blood of treated HIV-infected individuals. J Acquir Immune Defic Syndr. 2007;44:518–524.10.1097/QAI.0b013e3180315515
   PubMed Web of Science ®Google Scholar
• Geretti AM, Conibear T, Hill A, et al. Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz. J Antimicrob Chemother. 2014;69:1090–1097.10.1093/jac/dkt474
   PubMed Web of Science ®Google Scholar
• Derache A, Shin HS, Balamane M, et al. HIV drug resistance mutations in proviral DNA from a community treatment program. PLOS One. 2015;10:e0117430.10.1371/journal.pone.0117430
   PubMed Web of Science ®Google Scholar
• Gallien S, Charreau I, Nere ML, et al. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine. J Antimicrob Chemother. 2015;70:562–565.10.1093/jac/dku395
   PubMed Web of Science ®Google Scholar
• Lambert-Niclot S, Allavena C, Grude M, et al. Usefulness of HIV DNA resistance genotypic test in patient candidates for a RPV/TDF/FTC combination switch [Poster 22]. Paper presented at: XXIV International Drug Resistance Workshop; February 21–22, 2015; Seattle, WA.
   Google Scholar